APEXIGEN
Apexigen is a clinical-stage biopharmaceutical company developing antibody therapeutics for the treatment of cancer. It specializes in new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer.
APEXIGEN
Social Links:
Industry:
Biopharma Biotechnology Health Care Oncology Pharmaceutical
Founded:
2010-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.apexigen.com
Total Employee:
11+
Status:
Closed
Contact:
650 931-6235
Email Addresses:
[email protected]
Total Funding:
175.8 M USD
Technology used in webpage:
Google Maps IPv6 Akamai Hosted Comcast
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Decheng Capital
Decheng Capital investment in Series C - Apexigen
3E Bioventures
3E Bioventures investment in Series C - Apexigen
Oceanpine Capital
Oceanpine Capital investment in Series C - Apexigen
Virtus Inspire Ventures
Virtus Inspire Ventures investment in Series C - Apexigen
Delian Capital
Delian Capital investment in Series C - Apexigen
SV Tech Ventures
SV Tech Ventures investment in Series C - Apexigen
Decheng Capital
Decheng Capital investment in Series B - Apexigen
Virtus Inspire Ventures
Virtus Inspire Ventures investment in Series C - Apexigen
3E Bioventures
3E Bioventures investment in Series C - Apexigen
SV Tech Ventures
SV Tech Ventures investment in Series C - Apexigen
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-08 | Apexigen Appoints William Duke as Chief Financial Officer |
| 2022-01-04 | Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer |
| 2021-09-09 | Apexigen Announces Appointment of Dr. Frank Hsu as Chief Medical Officer |
Official Site Inspections
http://www.apexigen.com
- Host name: ewhserver1302.edgewebhosting.net
- IP address: 69.63.140.80
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Apexigen"
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Dupont previously served as a member of the Apexigen Board of Directors beginning in August 2020. His prior experience also includes roles as Global Head of Research and Development …See details»
Apexigen - Crunchbase Company Profile & Funding
Organization. Apexigen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Apexigen is a clinical-stage biopharmaceutical …See details»
Pyxis Oncology to Acquire Apexigen - GlobeNewswire
May 24, 2023 During Jay’s tenure, Pyxis Oncology transitioned from a preclinically focused organization to a clinical-stage company with two ongoing Phase 1 trials. I look forward to working closely with ...See details»
Apexigen Company Profile 2024: Valuation, Investors
Apexigen Inc is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to …See details»
Apexigen Completes Business Combination to Become a Publicly …
SAN CARLOS, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of …See details»
Combination of Apexigen, Inc. and Brookline Capital Acquisition …
Apexigen’s product candidates; Apexigen’s expectations with regard to the results of its clinical studies, preclinical studies and research and development programs; a nd Apexigen’s …See details»
Apexigen - Funding, Financials, Valuation & Investors - Crunchbase
Apexigen is registered under the ticker NASDAQ:APGN . Their stock opened with $10.00 in its Aug 1, 2022 IPO. Apexigen is funded by 11 investors. Decheng Capital and 3E Bioventures …See details»
Apexigen - LinkedIn
Apexigen | 1,438 followers on LinkedIn. Creating Transformative Immunotherapies for Patients with Cancer | Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new ...See details»
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Aug 23, 2023 Under the terms of the transaction, (i) each outstanding share of Apexigen common stock was converted into the right to receive 0.1725 (the “Exchange Ratio”) of a …See details»
Apexigen Announces Approximately $2.8 Million Private …
Jan 24, 2023 Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on …See details»
Pyxis Oncology to Acquire Apexigen - Yahoo Finance
May 24, 2023 All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025; PYX-201 and PYX-106 remain on track. Webcast to be held today, May 24, at 9:00 a.m. ETSee details»
Apexigen - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Apexigen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of Board …See details»
Apexigen Completes Business Combination to Become a
Aug 1, 2022 Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on …See details»
Apexigen Company Profile - Office Locations, Competitors ... - Craft
Apexigen is a company that develops antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its lead product reverses the systemic immune suppression …See details»
After megaround, Apexigen inks modest SPAC deal to advance …
Mar 18, 2022 Apexigen is braving a tough biotech stock market in a bid to land on the Nasdaq through a special purpose acquisition company merger. If the deal goes through as planned, …See details»
Apexigen Completes $123 Million Series C Financing To Advance …
Mar 24, 2020 Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on …See details»
Apexigen Announces Review of Strategic Alternatives and …
Feb 27, 2023 Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on …See details»
Apexigen, Inc. | Apexigen Presents New Data from a Phase 2 Trial ...
Sep 10, 2022 Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on …See details»
Apexigen Announces Positive Interim Results from Phase 2 Trial ...
SAN CARLOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the …See details»
Apexigen Announces Positive Interim Results from Phase 2
Nov 14, 2022 Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on …See details»